Switching to the Wegovy Pill: What You Need to Know

Can I switch to the Wegovy pill from another GLP-1 medication?

Yes, you can switch from another GLP-1 medicine to the Wegovy pill, but only with a prescriber guiding the change.

The Medicines and Healthcare products Regulatory Agency (MHRA) licenses medicines in the UK. They approved the Wegovy pill on 11 June 2026. The MHRA’s 2025 GLP-1 switching guidance gives a plain instruction — speak to a healthcare professional first.

Doing it alone carries a real cost. Switching without advice can increase the risk of side effects or reduce the new treatment’s effectiveness. GLP-1 medicines vary in strength and dosing rules, so the move is rarely like-for-like.

UK prescribers can now offer the Wegovy pill. NHS access requires an extra step on top of MHRA approval, so private prescriptions will likely come first. Switching from a weight loss injection to a pill will likely follow the similar principles across the GLP-1 class. 

Why do people switch to the Wegovy pill?

People consider the Wegovy pill mainly to escape weekly injections or to manage cost. A smaller group wants to keep the cardiovascular protection that semaglutide brings. Needle anxiety is the biggest driver we hear about. A daily tablet appeals to anyone who would rather not handle a weekly or daily injection, even a small one.

Cost is the second reason. Eli Lilly raised the UK list price of higher-dose Mounjaro sharply in 2025, with the highest dose climbing by around 170%. For some people, that change alone prompts a fresh look at their weight loss medication.

Now that the pill is approved, its private price sits close to the Wegovy injection rather than below it. The bigger saving is against Mounjaro at its higher doses, so for someone moving off pricier Mounjaro, the Wegovy pill can be the cheaper option. For someone already on Wegovy, the cost barely changes.

Supply is the other draw. Injectable GLP-1s like Wegovy and Mounjaro ran short across the UK through 2023 and 2024, when a surge in demand for weight loss outstripped production, and some people could not fill their prescriptions. Those shortages have largely eased, but a tablet that does not depend on pen manufacturing could make supply steadier in future.

The heart protection angle matters for a smaller group. Semaglutide is currently the only weight loss GLP-1 also licensed to lower cardiovascular risk. In the SELECT clinical trial, it cut the risk of heart attacks, stroke, or death from heart disease by about a fifth. 

That result came from a study of 17,604 adults. For someone who needs that protection, staying on semaglutide in pill form is appealing.

The results hold up, and it reassures people considering the move. In the OASIS 4 clinical trial, average weight loss on the Wegovy pill was 13.6% over 64 weeks. The placebo group, those given an inactive pill for comparison, lost roughly 2%. 

That average weight loss sits close to the weekly Wegovy 2.4mg injection. Prescribers therefore treat the pill as a serious option for long-term weight management.

What are the key principles of switching GLP-1 medications?

A safe switch depends on how long your current medicine stays in your body, and these timings vary widely. The figure behind this is a drug’s half-life, the time the body takes to clear half of a dose. The number that matters in practice is how long the medicine takes to leave your system completely.

Medicine (active drug)	Half-life	Time to clear your body	Gap before starting the pill
Saxenda or Nevolat (liraglutide)	~ 13 hours	About 3 days	Short: possibly the next day, or within a few days at most
Wegovy injection (semaglutide)	~ 1 week	Around 5 weeks	None needed: it is the same drug, so you start the pill one week after your last injection
Mounjaro (tirzepatide)	~ 5 days	About 4-5 weeks	Start the pill seven days after your last injected dose.

The licence sets one switch in stone: moving from the 2.4mg Wegovy injection to the 25mg pill, with no need to build up again. For other doses and switching from other medicines, our clinical team uses internal switching protocols that match your current injectable dose to the right pill strength.

Where you start below 25mg, you then build up gradually. The dosing schedule steps up every 30 days, so your body adjusts to each higher dose and side effects remain minimal. A prescriber reviews and approves each switch, and can start you lower if side effects were a problem before.

How do I transition from the Wegovy injection to the pill?

Switching from Wegovy injection to the pill is straightforward. Both forms of Wegovy work through the same active ingredient, semaglutide. Wegovy is the only GLP-1 switch currently with manufacturer guidance built into the product licence. Instructions are clear — one week after your last 2.4mg injection, you start the 25mg tablet once a day.

If you are not yet at the 2.4mg Wegovy injection maintenance dose, our clinical team uses a simple chart to match your current injection dose to the right pill dose. 

Wegovy injection dose	Wegovy pill dose
7.2mg, 2.4mg or 1.7mg	25mg
1mg or 0.5mg	9mg
0.25mg	4mg
–	1.5mg

The timing is the same whichever dose you are on:

• Take your final injection as normal.
• Wait seven days, to the day your next injection would have been due.
• Start the daily 25mg pill the following week. A last injection on a Monday means the pill starts the next Monday.

You must take Wegovy tablets on an empty stomach with a small sip of water. Then you wait at least 30 minutes before eating, drinking, or taking other medicines. The weekly injection has no such timing rule, so this daily habit is the biggest practical change to plan for.

Switching from Saxenda or Nevolat to the Wegovy pill

Switching from daily Saxenda or Nevolat injections to the Wegovy pill means changing the drug itself. Both Saxenda and Nevolat contain liraglutide, a different GLP-1 from semaglutide. 

Liraglutide is a daily injection, so you may be able to start the tablet the next day when your next dose is due. At the most, you should be able to start within a few days of stopping your injection.

Switching from Saxenda to the Wegovy pill will depend on your current injection dose. Speak to our clinical team, who will advise you on the dosing schedule.

Liraglutide also produces less weight loss on average than semaglutide. For people focused on losing weight, that gap is often the reason to make the change.

Switching from Mounjaro to the Wegovy pill

Switching from Mounjaro to the Wegovy pill is the largest jump, because the two drugs do not work the same way. Mounjaro contains tirzepatide, made by Eli Lilly, which acts on two gut hormone receptors at once. Semaglutide, the drug in the Wegovy pill, acts on only one. Our switching protocol matches the pill doses carefully and starts on the cautious side.

Mounjaro Injection Dose	Wegovy Pill Dose
15mg, 12.5mg, 10mg or 7.5mg	25mg
2.5mg or 5mg	9mg
–	4mg
–	1.5mg

Be ready for the possibility of less weight loss. In the head-to-head SURMOUNT-5 clinical trial, tirzepatide produced an average of 20.2% weight loss over 72 weeks. Injectable semaglutide reached about 13.7% over the same period. 

The oral pill is not expected to beat the injection, so the gap in effectiveness from Mounjaro is likely at least as wide. For some people, the difference is small, while for others it weighs heavily when choosing a weight loss treatment.

When should I see a doctor?

Speak to a prescriber before any switch, because changing GLP-1 medicines without advice can cause harm. Your starting dose is never about your current medicine alone. We also weigh your medical history, how well you have tolerated treatment so far, and any gaps since your last dose. The starting Wegovy pill dose we recommend is tailored to you. 

During the change, common side effects of the Wegovy pill follow the familiar GLP-1 pattern. They are mostly stomach-related and worst in the first few weeks of starting or stepping up in dose. 

Contact our clinical team if nausea, mild vomiting, or bowel changes are bothering you. The same goes for any question about whether to step your dose up or hold it steady. 

Call your GP or NHS 111 for symptoms that need a same-day look but are not an emergency. These include: 

• vomiting that stops you from keeping fluids down for over six hours
• signs of gallbladder trouble, such as yellowing skin or severe pain under your right ribs
• a new neck lump, hoarseness, or trouble swallowing, which may require a check of your thyroid

Stop the medicine and call 999 or go to A&E if you notice any of the following:

• severe stomach pain that spreads to your back, which can signal pancreatitis
• a severe allergic reaction, such as swelling of the face or throat, or trouble breathing
• signs of severe dehydration after being unable to keep fluids down
• any thoughts of harming yourself. Ask for the CRISIS team at A&E
• sudden changes to your vision, especially loss of sight in one eye. The MHRA has linked semaglutide, rarely, to a serious eye condition called NAION

Key takeaways

• Switching to the Wegovy pill is now possible in the UK. Following MHRA approval on 11 June 2026, UK prescribers can now offer it through private services. NHS approval is pending.
• Every switch needs a review: GLP-1 medicines differ in strength and timing, and changing them without advice is not safe.
• Moving from the Wegovy injection to the pill is the simplest switch. One week after your last 2.4mg injection, you start the 25mg tablet with no re-titration.
• We now have set protocols for switching from injections, matching your current dose to the right pill strength.
• Mounjaro users may see a smaller average weight loss after switching to semaglutide, so the choice weighs results against a likely lower cost than higher-dose Mounjaro.

References

Oral Semaglutide 25 mg in Adults with Overweight or Obesity (OASIS 4), New England Journal of Medicine, 2025 [Accessed 9 June 2026].

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5), New England Journal of Medicine, 2025 [Accessed 9 June 2026].

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT), New England Journal of Medicine, 2023 [Accessed 9 June 2026].

Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8), JAMA, 2022 [Accessed 9 June 2026].

GLP-1 medicines for weight loss and diabetes: what you need to know, GOV.UK (MHRA), 2025 [Accessed 9 June 2026].

Weight loss drug demand continues to grow in the UK – here’s what’s being done to keep supplies readily available, The Conversation, 2025 [Accessed 9 June 2026].

Considerations and interactions with GLP-1 receptor agonists, NHS Specialist Pharmacy Service, 2025 [Accessed 9 June 2026].

GLP-1 and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, Medicines and Healthcare products Regulatory Agency, 2026 [Accessed 9 June 2026]. 

Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), GOV.UK (MHRA Drug Safety Update), 2026 [Accessed 9 June 2026].

Saxenda 6 mg/mL solution for injection in pre-filled pen – Summary of Product Characteristics, electronic medicines compendium (eMC), 2025 [Accessed 9 June 2026].

Mounjaro KwikPen 2.5 mg solution for injection in pre-filled pen – Summary of Product Characteristics, electronic medicines compendium (eMC), 2025 [Accessed 9 June 2026]. 

First GLP-1 tablet for weight loss approved in the UK, Medicines and Healthcare products Regulatory Agency, 2026 [Accessed 11 June 2026]. 

Wegovy 25 mg tablets – Summary of Product Characteristics, electronic medicines compendium (eMC), 2026 [Accessed 17 June 2026].

Authorship